SEC Form 4 · accession 0001171843-17-007595
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter A Kiener
Officer — Chief Science Officer
Period of report
Dec 7, 2017
Accepted (ET)
Dec 11, 2017 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, Class A | Dec 7, 2017 | M | 50,000 | $8.33 | A | 52,023 | D | |
| Common Stock, Class AF2 | Dec 7, 2017 | S | 50,000 | $16.50 | D | 2,023 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $8.33 | Dec 7, 2017 | M | 50,000 | D | — | Oct 27, 2024 | Class A Common Stock | 50,000 | 242,567 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- F2Multiple lots for the same price for this order have been combined.
- F3Grant has a graded vesting schedule. Date Exercisable will vary for each vesting tranche.